Albert Lowe
Stock Analyst at Craig-Hallum
(2.06)
# 3,012
Out of 5,113 analysts
10
Total ratings
20%
Success rate
8.59%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Albert Lowe
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PVLA Palvella Therapeutics | Initiates: Buy | $175 | $83.97 | +108.41% | 1 | Dec 4, 2025 | |
| NGNE Neurogene | Initiates: Buy | $50 | $19.90 | +151.26% | 1 | Jun 17, 2025 | |
| ATOS Atossa Therapeutics | Initiates: Buy | $4 | $0.68 | +484.11% | 1 | Jun 5, 2025 | |
| IRD Opus Genetics | Initiates: Buy | $6 | $2.83 | +112.01% | 1 | Apr 11, 2025 | |
| SKYE Skye Bioscience | Maintains: Buy | $18 → $14 | $1.07 | +1,208.41% | 2 | Mar 21, 2025 | |
| SABS SAB Biotherapeutics | Initiates: Buy | $11 | $4.28 | +157.01% | 1 | Oct 9, 2024 | |
| CRDF Cardiff Oncology | Initiates: Buy | $8 | $2.00 | +300.00% | 1 | Sep 6, 2024 | |
| LCTX Lineage Cell Therapeutics | Initiates: Buy | $4 | $1.63 | +146.15% | 1 | Aug 20, 2024 | |
| PMVP PMV Pharmaceuticals | Initiates: Buy | $6 | $1.21 | +397.93% | 1 | May 13, 2024 |
Palvella Therapeutics
Dec 4, 2025
Initiates: Buy
Price Target: $175
Current: $83.97
Upside: +108.41%
Neurogene
Jun 17, 2025
Initiates: Buy
Price Target: $50
Current: $19.90
Upside: +151.26%
Atossa Therapeutics
Jun 5, 2025
Initiates: Buy
Price Target: $4
Current: $0.68
Upside: +484.11%
Opus Genetics
Apr 11, 2025
Initiates: Buy
Price Target: $6
Current: $2.83
Upside: +112.01%
Skye Bioscience
Mar 21, 2025
Maintains: Buy
Price Target: $18 → $14
Current: $1.07
Upside: +1,208.41%
SAB Biotherapeutics
Oct 9, 2024
Initiates: Buy
Price Target: $11
Current: $4.28
Upside: +157.01%
Cardiff Oncology
Sep 6, 2024
Initiates: Buy
Price Target: $8
Current: $2.00
Upside: +300.00%
Lineage Cell Therapeutics
Aug 20, 2024
Initiates: Buy
Price Target: $4
Current: $1.63
Upside: +146.15%
PMV Pharmaceuticals
May 13, 2024
Initiates: Buy
Price Target: $6
Current: $1.21
Upside: +397.93%